Хроническая реакция «трансплантат против хозяина» после аллогенной трансплантации гемопоэтических стволовых клеток

Обложка

Цитировать

Полный текст

Аннотация

Хроническая реакция «трансплантат против хозяина» (РТПХ) является тяжелым осложнением аллогенной трансплантации гемопоэтических стволовых клеток (ТГСК), в основе которого лежит иммунная дисрегуляция, приводящая к мультисистемному поражению с исходом в склерозирование тканей. Данное осложнение пролонгировано во времени и существенно нарушает качество жизни реципиентов ТГСК вследствие формирования вторичного иммунодефицита на фоне комбинированной иммуносупрессивной терапии, ограничения функций и реже – инвалидизации. Помимо активной профилактики хронической РТПХ необходим регулярный мониторинг пациентов для своевременного выявления первых признаков данного осложнения и проведения эффективной терапии. В кратком обзоре хронической РТПХ приведены новые подходы к определению и стадированию, а также указаны современные способы ее предотвращения и лечения.

Об авторах

Ю. В. Скворцова

ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России

Автор, ответственный за переписку.
Email: yuscvo@mail.ru
ORCID iD: 0000-0002-0566-053X

Скворцова Юлия Валериевна, д-р мед. наук, врач-гематолог, заместитель заведующего отделением трансплантации гемопоэтических стволовых клеток №2

117997, Москва, ул. Саморы Машела, 1 

Россия

Список литературы

  1. Zeiser R., Blazar B.R. Acute graftversus-host disease Biology, Prevention and Therapy. New Engl J Med 2017; 377 (22): 2167–79.
  2. Zeiser R., Fatoum H., Hashmi S.K. A personalized, organ-based approach to the treatment of chronic steroid-refractory gfart-versus-host disease. Blood Rev 2024; 63: 101142.
  3. Bachier C.R., Aggarwal S.K., Hennegan K., Milgroom A., Francis K., Dehipawala S., Rotta M. Epidemiology and treatment of chronic graft-versus-host disease post-allogeneic hematopoietic cell transplantation: a US claims analysis. Transpl Cell Ther 2021; 27 (6): 504. e1–6.
  4. Wingard J.R., Majhail N.S., Brazauskas R., Wang Z., Sobocinski K.A., Jacobsohn D., et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol 2011; 29 (16): 2230–9.
  5. Bhatia S., Francisco L., Carter A., Sun C.-L., Scott Baker K., Gurney J.G., et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the bone marrow transplant survivor study. Blood 2007; 110 (10): 3784–92.
  6. DeFilipp Z., Alousi A.M., Pidala J.A., Carpenter P.A., Onstad L.E., Arai S., et al. Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the chronic GVHD consortium. Blood Adv 2021; 5 (20): 4278–84.
  7. Majhail N.S., Brazauskas R., Rizzo J.D., Sobecks R.M., Wang Z., Horowitz M.M., et al. Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. Blood 2011; 117 (1): 316–22.
  8. Armenian S.H., Chemaitilly W., Chen M., Chow E.J., Duncan C.N., Jones L.W., et al. National Institutes of Health hematopoietic cell transplantation late effects initiative: the cardiovascular disease and associated risk factors working group report. Biology of blood and marrow transplantation. J Am Soc Blood Marrow Transplant 2017; 23 (2): 201–10.
  9. Arai S., Arora M., Wang T., Spellman S.R., He W., Couriel D.R., et al. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. Biology of blood and marrow transplantation. J Am Soc Blood Marrow Transplant 2015; 21 (2): 266–74.
  10. Inamoto Y., Storer B.E., Petersdorf E.W., Nelson J.L., Lee S.J., Carpenter P.A., et al. Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease. Blood 2013; 121 (25): 5098–103.
  11. Rodrıguez-Gil A., Carrillo-Cruz E., Marrero-Cepeda C., Rodriguez G., Perez-Simon J.A. Effect of vitamin D on graft-versus-host disease. Biomedicines 2022; 10 (5): 987.
  12. Jagasia M.H., Greinix H.T., Arora M., Williams K.M., Wolff D., Cowen E.W., et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2015; 21 (3): 389–401.
  13. Pidala J., Vogelsang G., Martin P., Chai X., Storer B., Pavletic S., et al. Overlap subtype of chronic graftversus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft-versus-Host Disease Consortium study. Haematologica 2012; 97 (3): 451–8.
  14. Schoemans H.M., Lee S.J., Ferrara J.L., Wolff D., Levine J.E., Schult K.R., et al.; EBMT (European Society for Blood and Marrow Transplantation) Transplant Complications Working Party and the “EBMT−NIH (National Institutes of Health) − CIBMTR (Center for International Blood and Marrow Transplant Research) GvHD Task Force. EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. Bone Marrow Transplant 2018; 53 (11): 1401–15.
  15. Filipovich A.H., Weisdorf D., Pavletic S., Socie G., Wingard J.R., Lee S.J., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11 (12): 945–56.
  16. MacDonald K.P., Hill G.R., Blazar B.R. Chronic graft-versus-host disease: biological insights from preclinical and clinical studies. Blood 2017; 129 (1): 13–21.
  17. Yi T., Chen Y., Wang L., Du G., Huang D., Zhao D., et al. Reciprocal diff entiation and tissue-specifi pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease. Blood 2009; 114 (14): 3101–12.
  18. Carlson M.J., West M.L., Coghill J.M., Panoskaltsis-Mortari A., Blazar B.R., Serody J.S. In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations. Blood 2009; 113 (6): 1365–74.
  19. Serody J.S., Hill G.R. The IL-17 differentiation pathway and its role in transplant outcome. Biol Blood Marrow Transplant 2012; 18 (1 Suppl): S56–61.
  20. Jin H., Ni X., Deng R., Song Q., Young J., Cassady K., et al. Antibodies from donor B cells perpetuate cutaneous chronic graft-versushost disease in mice. Blood 2016; 127 (18): 2249–60.
  21. Alexander K.A., Flynn R., Lineburg K.E., Kuns R.D., Teal B.E., Olver S.D., et al. CSF-1-dependant donor-derived macrophages mediate chronic graft-versus-host disease. J Clin Invest 2014; 124 (10): 4266–80.
  22. Erbel C., Akhavanpoor M., Okuyucu D., Wangler S., Dietz A., Zhao L., et al. IL-17A infl es essential functions of the monocyte/ macrophage lineage and is involved in advanced murine and human atherosclerosis. J Immunol 2014; 193 (9): 4344–55.
  23. Zorn E., Kim H.T., Lee S.J., Floyd B.H., Litsa D., Arumugarajah S., et al. Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graftversus-host disease. Blood 2005; 106 (8): 2903–11.
  24. Soiffer R.J., Lerademacher J., Ho V., Kan F., Artz A., Champlin R.E., et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood 2011; 117 (25): 6963–70.
  25. Devine S.M., Carter S., Soiffer R.J., Pasquini M.C., Hari P.N., Stein A., et al. Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network protocol 0303. Biol Blood Marrow Transplant 2011; 17 (9): 1343–51.
  26. Luznik L., Bolaños-Meade J., Zahurak M., Chen A.R., Smith B.D., Brodsky R., et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graftversus-host disease. Blood 2010; 115 (16): 3224–30.
  27. Raj K., Pagliuca A., Bradstock K., Noriega V., Potter V., Streetly M., et al. Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning. Biol Blood Marrow Transplant 2014; 20 (6): 890–5.
  28. Kitko C.L. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report Transplant Cell Ther 2021; 27 (7): 545–57.
  29. Скворцова Ю.В., Новичкова Г.А., Масчан А.А. Новое в патогенезе, диагностике и лечении хронической реакции «трансплантат против хозяина» после аллогенной ТГСК. Вопросы гематологии/ онкологии и иммунопатологии в педиатрии 2018; 17 (2): 121–35. doi: 10.24287/1726-1708-2018-172-121-135
  30. Wolff D., Schleuning M., von Harsdorf S., Bacher U., Gerbitz A., Stadler M., et al. Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 2011; 17 (1): 1–17.
  31. Carpenter P.A., Kitko C.L., Elad S., Flowers M.E., Gea-Banacloche J.C., Halter J.P., et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant 2015; 21 (7): 1167–87.
  32. Martin P.J., Inamoto Y., Carpenter P.A., Lee S.J., Flowers M.E. Treatment of chronic graft-versus-host disease: Past, present and future. Korean J Hematol 2011; 46 (3): 153–63.
  33. Flowers M.E., Martin P.J. How we treat chronic graft-versus-host disease. Blood 2015; 125 (4): 606–15.
  34. Flowers M.E., Storer B., Carpenter P., Rezvani A.R., Vigorito A.C., Campregher P.V., et al. Treatment change as a predictor of outcome among patients with classic chronic graft-versus-host disease. Biol Blood Marrow Transplant 2008; 14 (12): 1380–4.
  35. Inamoto Y., Flowers M.E., Sandmaier B.M., Aki S.Z., Carpenter P.A., Lee S.J., et al. Failure-free survival after initial systemic treatment of chronic graft-versus-host disease. Blood 2014; 124 (8): 1363–71.
  36. Greinix H.T., Worel N., Just U., Knobler R. Extracorporeal photopheresis in acute and chronic graft-versus-host disease. Transfus Apher Sci 2014; 50 (3): 349–57.
  37. Flowers M.E., Apperley J.F., van Besien K., Elmaagacli A., Grigg A., Reddy V., et al. A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versushost disease. Blood 2008; 112 (7): 2667–74.
  38. Olivieri A., Cimminiello M., Corradini P., Mordini N., Fedele R., Selleri C., et al. Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD. Blood 2013; 122 (25): 4111–8.
  39. de Masson A., Bouaziz J.D., Peffault de Latour R., Wittnebel S., Ribaud P., Rubio M.T., et al. Limited effi y and tolerance of imatinib mesylate in steroid-refractory sclerodermatous chronic GVHD. Blood 2012; 120 (25): 5089–90.
  40. Inamoto Y., Flowers M.E. Treatment of chronic graft-versus-host disease in 2011. Curr Opin Hematol 2011; 18 (6): 414–20.
  41. Penack O., Marchetti M., Ruutu T., Aljurf M., Bacigalupo A., Bonifazi F., et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantion Lancet Haematol 2020; 7 (2): e157–67.
  42. Couriel D., Carpenter P.A., Cutler C., Bolaños-Meade J., Treister N.S., Gea-Banacloche J., et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant 2006; 12 (4): 375–96.
  43. [Electronic resource] URL: http://asbmt.affiniscape.com/associations/11741/files/DispensaryGuidelines.pdf) (accessed 03.06.2020).
  44. Vigorito A.C., Campregher P.V., Storer B.E., Carpenter P.A., Moravec C.K., Kiem H.P., et al. Evaluation of NIH consensus criteria for classifi of late acute and chronic GVHD. Blood 2009; 114 (3): 702–8.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© Скворцова Ю.В., 2025

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution 4.0 International License.